Use of Aspirin postdiagnosis improves survival for colon cancer patients

British Journal of Cancer

Volumn 106, Issue 9, 2012, Pages 1564-1570

  Bastiaannet, E ^a   Sampieri, K ^b   Dekkers, O M ^a   De Craen, A J M ^a   Van Herk Sukel, M P P ^c   Lemmens, V ^d   Van Den Broek, C B M ^a   Coebergh, J W ^d,e   Herings, R M C ^c   Van De Velde, C J H ^a   Fodde, R ^b   Liefers, G J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d The Netherlands   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

aspirin; Colorectal cancer; NSAIDs; population based; survival

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OVERALL SURVIVAL; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; RECTAL NEOPLASMS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84860250352     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.101     Document Type: Article

References (34)

1. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860
2. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, Keown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899 (Pubitemid 36297997)
3. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142 (Pubitemid 47010839)
4. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302: 649-658
5. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91: 894-899 (Pubitemid 32178662)
6. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, Potter JD, Ulrich CM (2011) Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut 60: 491-498
7. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La VC, Meyskens F, Senn HJ, Thun M (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507
8. Dihlmann S, Klein S, Doeberitz Mv MK (2003) Reduction of beta-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated beta-catenin Mol Cancer Ther 2: 509-516
9. Dihlmann S, Siermann A, von Knebel DM (2001) The nonsteroidal antiinflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 20: 645-653 (Pubitemid 32156189)
10. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009) Aspirin, salicylates, and cancer. Lancet 373: 1301-1309
11. Fuchs CS, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, Saltz LB, Schilsky R, Mayer RJ. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. ASCO (2005) Ref type: Abstract
12. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. NEngl J Med 333: 609-614
13. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121: 241-246
14. Herschman HR (1996) Prostaglandin synthase 2. Biochim Biophys Acta 1299: 125-140 (Pubitemid 26007741)
15. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472
16. Keating NL, Landrum MB, Klabunde CN, Fletcher RH, Rogers SO, Doucette WR, Tisnado D, Clauser S, Kahn KL (2008) Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26: 2532-2537
17. Neugut AI (2009) Aspirin as adjuvant therapy for colorectal cancer: a promising new twist for an old drug. JAMA 302: 688-689
18. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377: 31-41
19. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376: 1741-1750
20. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890 (Pubitemid 36297996)
21. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J (1997) Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 94: 2869-2873 (Pubitemid 27157231)
22. Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167: 492-499
23. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G (2007) Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1: 389-402 (Pubitemid 47506537)
24. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, Sunami E, Nita ME, Ishihara S, Yano H, Tsuruo T, Shibata Y, Muto T (1999) Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 81: 1274-1279
25. Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340 (Pubitemid 27157312)
26. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705-716 (Pubitemid 28257578)
27. van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, Vreugdenhil G, Pruijt JF, Coebergh JW, Herings RM (2010) New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer 46: 395-404
28. Vandenbroucke JP (2008) Observational research, randomised trials, and two views of medical science. PLoS Med 5: e67
29. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232-235
30. Wang Y, Chen X, Zhu W, Zhang H, Hu S, Cong X (2006) Growth inhibition of mesenchymal stem cells by aspirin: involvement of the WNT/betacatenin signal pathway. Clin Exp Pharmacol Physiol 33: 696-701 (Pubitemid 44060760)
31. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW (2005) Colorectal cancer. Lancet 365: 153-165 (Pubitemid 40091806)
32. Williams CS, Sheng H, Brockman JA, Armandla R, Shao J, Washington MK, Elkahloun AG, DuBois RN (2001) A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 3: 428-436 (Pubitemid 32988813)
33. Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM (2003) Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 63: 586-592 (Pubitemid 36158135)
34. Yao M, Zhou W, Sangha S, Albert A, Chang AJ, Liu TC, Wolfe MM (2005) Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin Cancer Res 11: 1618-1628 (Pubitemid 40315247)